166732 Science for tobacco regulation: What we know and what we need to know

Monday, November 5, 2007: 4:48 PM

Dorothy K. Hatsukami, PhD , Transdisciplinary Tobacco Use Research Center, University of Minnesota, Minneapolis, MN
     
This presentation will provide a conceptual model for testing tobacco products in humans and provide an overview of the existing science in this area. The conceptual model involves: a) pre-clinical testing of the product as described by Dr. David Ashley, b) human laboratory and clinical trials involving testing of the products and determining consumer perception of these products, and c) post-marketing surveillance. Examples of the current science in the following areas will be described: a) the varying levels of toxic constituents and nicotine in tobacco products; b) biomarkers for exposure and toxicity; c) the relationship between exposure and toxicity biomarkers and constituent yields in the product; d) the different methods to test potential reduced exposure products (PREPs); e) consumer perception testing of PREPs. Future research requirements to address the science needs for tobacco product regulation will be discussed. Funded by NIH P50 DA013333 and NCI N01 PC-64402

Learning Objectives:
a) to learn about the different areas of investigation for tobacco product testing; b) to learn about the current science being conducted in these areas; c) to learn about future research needs in the area of product testing.

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: Generating Science to Drive Comprehensive Tobacco Regulatory Policy: Creating the Research Blueprint
See more of: Alcohol, Tobacco, and Other Drugs